香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （ 於開曼群島註冊成立的有限公司 ） （股份代號：06160） 授出購股權及受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2023年9月29 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向十一名承授人授出可 認購合共14,822股美國存託股份的購股權並向二百六十名承授人授出涉及合共 103,323股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的購股權 於2023年9月29日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予十一 名承授人可認購合共14,822股美國存託股份的購股權。 授出購股權詳情 購股權詳情如下： | 授出日期： | 2023年9月29日 | | --- | --- | | 承授人數目： | 十一名 | | 已授出購股權涉及的 | 192,686 | | 相關股份數目： | ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2023年10月6日 I. 法定/註冊股本變動 II. 已發行股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 06160 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 9,500,000,000 | USD | | 0.0001 USD | | 950,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 9,500,000,000 | USD | | 0.0001 USD | | 950,000 | ...

公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 呈交日期： 2023年10月3日 | 第一章節 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 不適用 | | | | | 於香港聯交所上市(註11) | 是 | | | | | 證券代號 (如於香港聯交所上市) | | 06160 | 說明 | | | | | | | | | | | | (註6及7) | 發行股份 | 股份數目 | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | | | 每股發行價 (註1及7) | | 上一個營業日 的每股收市價 (註5) | | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | | 於下列日期開始時的結存(註2) | | 2023年9月15日 ...

2023 中期報告 目錄 | | 頁次 | | --- | --- | | 公司資料 | 2 | | 前瞻性陳述 | 4 | | 管理層討論及分析 | 7 | | 其他資料 | 35 | | 未經審核中期簡明綜合經營表 | 82 | | 未經審核中期簡明綜合全面虧損表 | 83 | | 未經審核中期簡明綜合資產負債表 | 84 | | 未經審核中期簡明綜合股東權益報表 | 86 | | 未經審核中期簡明綜合現金流量表 | 87 | | 未經審核中期簡明綜合財務報表附註 | 89 | | 釋義 | 143 | | 技術詞彙 | 147 | 1 百濟神州有限公司 • 2023 中期報告 公司資料 董事會 執行董事 歐雷強先生 （主席兼首席執行官） 非執行董事 王曉東博士 獨立非執行董事 Margaret Han Dugan博士 Donald W. Glazer先生 Michael Goller先生 Anthony C. Hooper先生* Ranjeev Krishana先生 Thomas Malley先生 Alessandro Riva博士 Corazon (Corsee) D. Sanders博士 易清清先生 ...

Financial Performance - BeiGene reported a significant increase in revenue, achieving $500 million in the first half of 2023, representing a 25% year-over-year growth[8]. - Total revenue for the six months ended June 30, 2023, increased by 60.9% to $1,043.1 million compared to $648.2 million for the same period in 2022, primarily driven by increased sales of Baiyueze® and Baizean®[24]. - Product revenue, net for the six months ended June 30, 2023, was $964.0 million, representing a 70.3% increase from $566.1 million in the same period of 2022[24]. - The company expects to achieve a revenue target of $1.2 billion for the full year 2023, representing a 20% growth compared to 2022[9]. - The company reported a net loss of $729.6 million for the six months ended June 30, 2023, compared to a net loss of $1 billion for the same period last year[46]. - The company’s total comprehensive loss for the six months ended June 30, 2023, was $(795,838) thousand, compared to $(1,101,324) thousand in the same period of 2022, reflecting an improvement of approximately 28%[157]. Research and Development - BeiGene's R&D expenses for the first half of 2023 were approximately $300 million, reflecting a 15% increase compared to the same period last year[9]. - Research and development expenses for the six months ended June 30, 2023, were $831.3 million, an increase of 8.2% from $768.1 million in the same period of 2022[24]. - The company is advancing several drug candidates, including BTK inhibitor Zebutini and PD-1 monoclonal antibody Tarelizumab, among others[20]. - The company has conducted over 120 clinical trials with more than 21,000 participants across approximately 45 regions[11]. - The company has established one of the largest and most efficient oncology research teams globally, comprising approximately 1,100 researchers, generating $1.4 billion in collaboration payments[13]. Product Development and Commercialization - The company anticipates launching two new drug candidates by the end of 2023, aiming for regulatory approval in key markets[9]. - The company has three self-developed and approved drugs: Baiyueze® (Zebutinib), Baizean® (Tislelizumab), and Baihuize® (Pamiparib)[11]. - Baiyueze® has been approved in multiple markets including the US, China, EU, UK, Canada, and Australia, while Baizean® and Baihuize® are currently approved in China[11]. - The company has authorized 14 approved drugs for commercialization in the Chinese market[11]. - The company is actively pursuing acquisitions to bolster its pipeline and enhance its competitive position in the biopharmaceutical industry[9]. Market Expansion - BeiGene is expanding its market presence in Europe and Asia, with plans to increase its sales force by 20% in these regions[9]. - The company is actively expanding its commercial capabilities in the Asia-Pacific region and through distributor partners in Latin America and other emerging markets[15]. - The company has entered into strategic partnerships to enhance its drug development capabilities, which are expected to yield significant benefits in the coming years[9]. Financial Position and Cash Flow - The company has total assets reached $2 billion as of June 30, 2023, reflecting a 10% increase from the previous year[9]. - Cash, cash equivalents, and short-term investments totaled approximately $1.2 billion in USD and RMB 16.3 billion (approximately $2.2 billion) as of June 30, 2023[38]. - The company reported a net cash inflow from financing activities of $146,212 thousand for the six months ended June 30, 2023, compared to a net outflow of $(28,847) thousand for the same period in 2022[162]. - The company plans to meet its significant cash needs through a combination of equity sales, debt financing, collaboration arrangements, and other available resources[54]. - The company expects its existing cash, cash equivalents, and short-term investments to meet operational and capital expenditure needs for at least the next 12 months[46]. Corporate Governance - The company emphasizes the importance of strong corporate governance to protect shareholder interests and enhance corporate value[137]. - The Audit Committee is composed of three independent non-executive directors, with Mr. Anthony C. Hooper appointed as the Chairman since September 13, 2023[138]. - The company has implemented its own insider trading policy, which is in line with the standards set for directors trading in the company's securities[140]. - The company will continue to review and monitor corporate governance practices to ensure compliance with the corporate governance code[139]. Shareholder Structure - The largest shareholder, Orey Qiang, holds 26,821,201 shares, representing approximately 1.96% of the total shares[76]. - As of June 30, 2023, Amgen Inc. holds 246,269,426 shares, representing 17.96% of the total shares[82]. - The overall shareholding structure indicates a significant concentration of ownership among key executives and their families, which may impact corporate governance[76]. - The company has a family trust structure in place for several shareholders, indicating a strategic approach to shareholding and estate planning[78]. Stock Options and Employee Incentives - The company has granted stock options that could allow Orey Qiang to acquire up to 24,849,647 additional shares, subject to vesting conditions[77]. - The company has established performance targets and/or service conditions for restricted stock units, which may include continued employment during the vesting period[97]. - The total number of unexercised stock options as of June 30, 2023, was 58,683,144[111]. - The company has maintained a steady exercise price range for stock options, with prices fluctuating between $2.27 and $25.54 over the years[104]. Strategic Investments - The company is investing significantly in a 42-acre production and clinical R&D center in Hopewell, New Jersey, with total construction costs reaching $314.7 million[63]. - The company is actively expanding its global footprint through strategic investments in various countries, enhancing its capabilities in medical and pharmaceutical sectors[167][168]. - The company has engaged with leading global biopharmaceutical companies to develop and commercialize innovative drugs, enhancing its global clinical development and commercialization capabilities[163].

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2023年9月18日 | 發行股份 | | | 已發行股份佔 有關股份發行前的 現有已發行股份數目 | | 每股發行價 | 上一個營業日 | 發行價較市值的折讓/ | | | 股份數目 | 的每股收市價 | 溢價幅度(百分比) | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | (註6及7) | | | 百分比 (註4、6及7) | | (註1及7) | (註5) | (註7) | | | | | | | | 於下列日期開始時的結存(註2) | 2023年8月31日 | 115,055,260 | | | | | | | | | | | | | 1). 其他 (請註明) | | 0 | | % | | | | | | | | | % | | 不适用 | | | | | | | | | | | | ...

歐雷強先生 （主席兼首席執行官） 非執行董事 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 董事名單及其角色與職能 百濟神州有限公司（「本公司」）董事會（「董事會」）成員載於下文。 執行董事 | | | | | | 商業及 | | --- | --- | --- | --- | --- | --- | | | | | 提名及 | | 醫學事務 | | | 審計 | 薪酬 | 企業管 | 科學諮詢 | 諮詢 | | | 委員會 | 委員會 | 治委員會 | 委員會 | 委員會 | | 歐雷強先生 | | | | | | | 王曉東博士 | | | | CC | | | Margaret Han Dugan博士 | | C | | M | M | | Donald W. Glazer先生 | | | C | | | | Michael Goller先生 | | | M | M | | | Anthony C. Hooper先生 | C | | M | | C | | Ranjeev Krishana先生 | | M | | | M | | Thomas ...

A股代码：688235 A股简称：百济神州 公告编号：2023-029 港股代码：06160 港股简称：百济神州 美股代码：BGNE 百济神州有限公司 关于董事会审计委员会主席变更的公告 2023 年 9 月 15 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 经百济神州有限公司（以下简称"公司"）董事会审议通过，自 2023 年 9 月 13 日起，Anthony C. Hooper 先生获委任为董事会审计委员 会（以下简称"审计委员会"）主席。Thomas Malley 先生不再担任审 计委员会主席，但将继续担任审计委员会成员。 审计委员会由三名成员构成，包括 Anthony C. Hooper 先生、 Thomas Malley 先生以及 Corazon (Corsee) D. Sanders 博士。Anthony C. Hooper 先生为审计委员会主席。 特此公告。 百济神州有限公司董事会 ...

| | | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2023年9月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 06160 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 9,500,000,000 | USD | | 0.0001 USD | | 950,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 9,500,000,000 | USD | | 0.0001 USD | | 950,000 | | 2. 股份分類 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 授出購股權及受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2023年8月31 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向三名承授人授出可認購 合共4,178股美國存託股份的購股權並向二百四十五名承授人授出涉及合共65,001 股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的購股權 於2023年8月31日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予三名 承授人可認購合共4,178股美國存託股份的購股權。 授出購股權詳情 購股權詳情如下： 1 授出日期： 2023年8月31日 承授人數目： 三名 已授出購股權涉及的 相關股份數目： 54,314 購股權總數（美國存託股份）: 4,178 因已授出購股權獲行使而可予 認購的新美國 ...